Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc.

Fintel reports that on July 29, 2025, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Fintel reports that on July 30, 2025, Barclays upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO ...

Norfolk Southern ( NSC) was down 2% in premarket trade after Union Pacific Corporation (UNP) and the company announced an ...

We recently published 11 Stocks That Jim Cramer Recently Talked About. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the ...

Rare disease and gene therapy stocks, battered in recent months by clinical and commercial setbacks, will likely benefit from ...

Sarepta Therapeutics shares are halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) ...